Inhibrx (NASDAQ:INBX) Sees Large Volume Increase

Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 1,719,541 shares were traded during mid-day trading, an increase of 139% from the previous session's volume of 718,804 shares.The stock last traded at $34.92 and had previously closed at $34.97.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on INBX shares. JMP Securities reissued a "market perform" rating on shares of Inhibrx in a research note on Tuesday, January 23rd. Lifesci Capital cut shares of Inhibrx from an "outperform" rating to a "market perform" rating in a research note on Tuesday, January 23rd.

Inhibrx Stock Down 0.8 %

The business's 50 day moving average is $36.51 and its 200-day moving average is $28.74. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -6.92 and a beta of 2.91. The company has a debt-to-equity ratio of 4.78, a quick ratio of 5.25 and a current ratio of 5.24.

Inhibrx (NASDAQ:INBX - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.66). Inhibrx had a negative return on equity of 590.78% and a negative net margin of 13,408.95%. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $0.10 million. On average, sell-side analysts predict that Inhibrx, Inc. will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Inhibrx

Several institutional investors and hedge funds have recently added to or reduced their stakes in INBX. AJOVista LLC purchased a new position in shares of Inhibrx during the 4th quarter worth $26,000. Quadrant Capital Group LLC purchased a new position in shares of Inhibrx during the 4th quarter worth $26,000. Quarry LP purchased a new position in shares of Inhibrx during the 4th quarter worth $28,000. Signaturefd LLC raised its holdings in shares of Inhibrx by 4,637.5% during the 4th quarter. Signaturefd LLC now owns 758 shares of the company's stock worth $29,000 after acquiring an additional 742 shares during the period. Finally, West Tower Group LLC purchased a new position in shares of Inhibrx during the 4th quarter worth $87,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.